A trio of biotechs consolidate as M&A fails to materialize at JPM

Many left last week’s J.P. Morgan Healthcare Conference a bit disappointed after relatively quiet M&A activity failed to wake up a bear industry slumbering through hibernation. Three separate mergers announced Tuesday show that many biotechs with a core asset are looking for new ways to survive.